Enhanced end-organ protection in the absence of increased plasma potassium with combined mineralocorticoid receptor (MR) antagonist and amiloride therapy

被引：0

|

作者：

Stier, CT ^{[1
]}

Sepehrdad, R ^{[1
]}

Singh, GD ^{[1
]}

Chander, PN ^{[1
]}

机构：

[1] New York Med Coll, Valhalla, NY 10595 USA

来源：

FASEB JOURNAL | 2005年 / 19卷 / 05期

关键词：

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

收藏

页码：A1188 / A1188

页数：1

相关论文

共 2 条

[1] Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
Kolkhof, P.
Hartmann, E.
Freyberger, A.
Pavkovic, M.
Mathar, I.
Sandner, P.
Droebner, K.
Joseph, A.
Eitner, F.
Hueser, J.
EUROPEAN HEART JOURNAL, 2021, 42 : 2284 - 2284
[2] Finerenone, a novel selective non-steroidal mineralocorticoid receptor antagonist with a balanced cardiorenal tissue distribution confers pronounced end organ protection at low natriuretic doses
Kolkhof, P.
Delbeck, M.
Kretschmer, A.
Steinke, W.
Hartmann, E.
Baerfacker, L.
Eitner, F.
Albrecht-Kuepper, B.
Schaefer, S.
EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 210 - 210